학술논문
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17
Document Type
Article
Author
Source
In: European Journal of Cancer . (European Journal of Cancer, March 2024, 200)
Subject
Language
English
ISSN
18790852
09598049
09598049